Amphipathic a-helical antimicrobial peptides comprise a class of broad-spectrum agents that are used against pathogens. We\r\ndesigned a series of antimicrobial peptides, CP-P (KWKSFIKKLTSKFLHLAKKF) and its derivatives, and determined their\r\nminimum inhibitory concentrations (MICs) against Pseudomonas aeruginosa, their minimum hemolytic concentrations (MHCs)\r\nfor human erythrocytes, and the Therapeutic Index (MHC/MIC ratio). We selected the derivative peptide K11, which had the\r\nhighest therapeutic index (320) among the tested peptides, to determine the MICs against Gram-positive and Gram-negative\r\nbacteria and 22 clinical isolates including Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, Pseudomonas\r\naeruginosa, Staphylococcus epidermidis, and Klebsiella pneumonia. K11 exhibited low MICs (less than 10 �µg/mL) and broadspectrum\r\nantimicrobial activity, especially against clinically isolated drug-resistant pathogens. Therefore, these results indicate\r\nthat K11 is a promising candidate antimicrobial peptide for further studies.
Loading....